Palatin Technologies, Inc. Common Stock (NASDAQ:PTN) — Market Cap & Net Worth
Market Cap & Net Worth: Palatin Technologies, Inc. Common Stock (PTN)
Palatin Technologies, Inc. Common Stock (NASDAQ:PTN) has a market capitalization of $21.12 Million ($21.12 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24957 globally and #5252 in its home market, demonstrating a -15.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Palatin Technologies, Inc. Common Stock's stock price $11.87 by its total outstanding shares 1779275 (1.78 Million). Review Palatin Technologies, Inc. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
Palatin Technologies, Inc. Common Stock Market Cap History: 2026 to 2026
Palatin Technologies, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $21.12 Million to $21.12 Million (0.00% CAGR).
Palatin Technologies, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Palatin Technologies, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTN by Market Capitalization
Companies near Palatin Technologies, Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Palatin Technologies, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Palatin Technologies, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Palatin Technologies, Inc. Common Stock's market cap moved from $21.12 Million to $ 21.12 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $21.12 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Palatin Technologies, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.12 Million USD |
| MoneyControl | $21.12 Million USD |
| MarketWatch | $21.12 Million USD |
| marketcap.company | $21.12 Million USD |
| Reuters | $21.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more